Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis.

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Based on data provided by Novo Nordisk (and others), the FDA has determined that Novo is now producing sufficient quantities of GLP-1 drugs to satisfy the market: "Supply is currently meeting or ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Novo Nordisk has established itself as a global leader in the treatment of diabetes and obesity, two of the most pressing health challenges of our time. The company's GLP-1 receptor agonist ...